Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SSGJ-718
- Development stage
- Unknown
- Lead developer
- 3S Guojian Pharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
SSGJ-718 is a first-in-class recombinant bispecific monoclonal antibody designed to simultaneously target and neutralize tumor necrosis factor-like ligand 1A (TL1A) and interleukin-23 subunit p19 (IL-23p19). Developed by Sunshine Guojian Pharmaceutical, a subsidiary of 3SBio, the therapeutic candidate is designed to address immune-mediated inflammatory diseases, specifically inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn's disease. By concurrently blocking the TL1A/DR3 and IL-23/Th17 signaling pathways, SSGJ-718 aims to provide a synergistic therapeutic effect that controls both the initiation and maintenance of intestinal inflammation, as well as potentially mitigating tissue fibrosis. The drug received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA) in October 2026 to initiate clinical trials.
- Other names
- 718
02
Targets
IL23R (Interleukin-23 Receptor)TL1A (TNF-like cytokine 1A)DR3 (Tumor necrosis factor receptor superfamily member 25)IL23A (Interleukin-23 p19 Subunit)
Beyond the preview
Go deeper on SSGJ-718.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SSGJ-718.